Ondansetron and opiate craving. A novel pharmacological approach to addiction.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 7795925.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pharmacological approaches to opiate addiction have for the most part been limited to a role in detoxification. A high percentage of patients who complete detoxification programmes relapse. In the present study, we used a simple laboratory method to investigate suggestions from preclinical studies that 5-(hydroxytryptamine) HT3 receptor antagonists have a role in the treatment of addiction. We showed that addicts stably maintained on methadone experienced significant craving, dysphoria, and withdrawal-like symptoms when exposed to a video containing drug-related cues. The craving was not lessened by treatment with the 5-HT3 receptor antagonist, ondansetron (4 mg orally). Our current findings do not support a role for 5-HT3 receptor agonists in the reduction of craving in opiate addicts.
Medical subject headings
- Methadone
- Narcotics
- Ondansetron
- Substance Withdrawal Syndrome
- Substance-Related Disorders